The European Association for Cancer Research
Advancing cancer research - from basic research to prevention, treatment and care
Constitution
Article I Name The Association shall be called "European Association for Cancer Research". It is a non profit-making, voluntary organization.
Article II Duration
The Association, founded on January 9th 1968, is established in Amsterdam,
the Netherlands, for a period of 29 years and 11 months until December
9th 1997. The duration was extended on April 6th 1993, in Brussels, Belgium,
for a period of 50 years until December 9th 2047.
Article III Aim
The aim of the Association shall be the advancement of cancer research.
Article IV Membership
The Association shall consist of active, student, emeritus, honorary, distinguished
and sustaining members. The first five categories of membership shall
be open to individual scientists as well as members of scientific societies
engaged in cancer research. The last category is open to organizations
in recognition of regular contributions to the aims and activities of
the Association. Members will be elected according to By-Laws approved
by the General Assembly.
Article V Organization
The Association shall include: (a) General Assembly (b) Council (c) Executive
Committee (d) Nominating Committee (e) Honorary Fellows
(a) The General Assembly as the supreme governing body of the Association
is composed of the members of the Association. It should meet at least
every two years.
(b) The Council is an advisory body and meets annually.
Its membership comprises representatives of ‘National Societies’ affiliated
to EACR; representatives of ‘Sustaining Member’ organisations; members
elected from countries which meet the criteria for Council representation
as set out in the By-Laws; three openly elected seats; and seats for non-European
countries which are geographically and/or scientifically closely linked
to Europe and share the aims of the Association.
The term of office for each elected Council member is four years.
(c) The Executive Committee will be elected by the General Assembly. It
will be composed of 5 Members, 2 Representative for Young Researchers and the following
officers: 1) President, 2) President-Elect, 3) Past-President, 4) Secretary
5) Treasurer and 6) Executive Director. The members will be elected for
a term of four years in a way that at least two will retire every two
years. Representative for Young Researchers will be elected for a term of four years
and are eligible for subsequent election as members. To secure a balance
of new and experienced members, the EC may wish to recommend a two year
extension of a member or Young Representative’s term of office to the
General Assembly
The officers will be elected for a term of two years. The Secretary and
Treasurer are eligible for re-election. The position of Executive Director
is ex-officio.
The Executive Committee shall in consultation with the Nominating Committee
fill any incidental vacancies arising in membership of the Council and
the Executive Committee by co-opting another member who shall hold office
for the remainder of the period of office of the member whom he or she
replaces. The co-opted member shall be eligible for election to the Executive
Committee and the Council immediately thereafter.
(d) The Nominating Committee is composed of the Past-President (chair)
and four members of the Council, elected by the Council.
(e) Acting on behalf of the General Assembly, the Executive Committee shall
have the authority to nominate and to elect one or more Honorary Fellows
of the EACR and one or more Distinguished Members of the EACR on the occasion
of major meetings of the Association. This fellowship or this membership
shall be awarded to a person who has shown exceptional service in furthering
the aims, objectives and activities of the Association. The Honorary Fellows
and the Distinguished Members of the EACR will be entitled to Honorary
Life Membership of the EACR and shall be consulted by the Executive Committee
in an advisory capacity in the general affairs and policies of the Association.
Article VI Changes in the Constitution and Dissolution of the
Association
Amendments to the Constitution and proposals for the dissolution of the
Association shall first be submitted to the Secretary in writing for consideration
by the Executive Committee. The proposed amendments or dissolution with
the recommendations of the Executive Committee shall be submitted to the
Council and the General Assembly either at a business meeting or by correspondence.
A two third majority vote of those present at the General Assembly or of
those voting by correspondence shall be required for adoption of the proposed
amendment or dissolution of the Association. In the event of the dissolution
of the Association becoming effective, the General Assembly shall designate
trustees charged with the liquidation of the Association's assets which
will be donated to one or more non-profit making organizations.
Incorporated in the Netherlands, Koninkiljk besluit d.d.2-4-1970 nr.88
The Constitution was amended in Nottingham 1975, in Vienna 1979, in Copenhagen
1983, in Brussels 1993, in Stockholm 1998 in Granada 2002, in Innsbruck 2004
and in Nottingham 2007 and 2008.
Further information: By-laws
Members' Log in
Latest News
EACR-21 participants praise quality of the Scientific Programme in Feedback Survey
Results of EACR members Survey for Eurocancercoms published and further comments invited
New Updated Guidelines for the Welfare and Use of Animals in Cancer Research
2010 EACR Year Book now available online:
2010 EACR Award winners announced
Members' Items
e-news bulletin, SPAM filters and Junk Mail
2009 Summer Symposia Programme Book and Abstracts are now available to members online
View newsletters, publications and surveys >
European Journal of Cancer - Online Subscription offer
Keep contact details up to date to receive regular EACR news by e-mail and air-mail
2010 Membership Fees: Information about Invoicing and Payment Methods
Jobs and Study Opportunities
Click a title for full information
Latest Opportunitities
Post-doctoral Position, Vall d’Hebron Institute of Oncology, Barcelona
World Cancer Research Fund (WCRF) International: Application Announcement for 2010/11 Grant Cycle
Director, Drug Discovery, Sage Bionetworks, Seattle, WA
